Pelthos Therapeutics Inc. - 8-K Filing
Pelthos Therapeutics reports Q3 2026 Zelsuvmi revenue of $15.2 million and announces definitive merger agreement with Castle Creek Biosciences. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PTHS